[go: up one dir, main page]

LUC00195I2 - - Google Patents

Download PDF

Info

Publication number
LUC00195I2
LUC00195I2 LU00195C LUC00195C LUC00195I2 LU C00195 I2 LUC00195 I2 LU C00195I2 LU 00195 C LU00195 C LU 00195C LU C00195 C LUC00195 C LU C00195C LU C00195 I2 LUC00195 I2 LU C00195I2
Authority
LU
Luxembourg
Application number
LU00195C
Original Assignee
Novartis Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37908343&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LUC00195(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma Ag filed Critical Novartis Pharma Ag
Publication of LUC00195I2 publication Critical patent/LUC00195I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/50—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
LU00195C 2005-11-09 2021-01-11 LUC00195I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73509305P 2005-11-09 2005-11-09
US73554105P 2005-11-10 2005-11-10
US78933206P 2006-04-04 2006-04-04
US82208606P 2006-08-11 2006-08-11

Publications (1)

Publication Number Publication Date
LUC00195I2 true LUC00195I2 (fr) 2024-10-04

Family

ID=37908343

Family Applications (1)

Application Number Title Priority Date Filing Date
LU00195C LUC00195I2 (fr) 2005-11-09 2021-01-11

Country Status (36)

Country Link
US (12) US8877938B2 (fr)
EP (3) EP3685833A1 (fr)
JP (3) JP4824754B2 (fr)
KR (2) KR101432821B1 (fr)
CN (2) CN101098689B (fr)
AR (1) AR057882A1 (fr)
AU (1) AU2006311481B2 (fr)
BR (2) BR122013025375B8 (fr)
CA (1) CA2590511C (fr)
CY (4) CY1115004T1 (fr)
DK (2) DK1948158T3 (fr)
EC (1) ECSP14019136A (fr)
ES (2) ES2823749T3 (fr)
FR (2) FR16C0018I2 (fr)
GT (1) GT200700055A (fr)
HR (2) HRP20140274T1 (fr)
HU (3) HUE050870T2 (fr)
IL (2) IL184027A (fr)
JO (1) JO3492B1 (fr)
LT (3) LT2340828T (fr)
LU (1) LUC00195I2 (fr)
MA (1) MA30128B1 (fr)
MX (1) MX2007008075A (fr)
MY (1) MY145462A (fr)
NO (3) NO337288B1 (fr)
NZ (2) NZ594006A (fr)
PE (2) PE20070803A1 (fr)
PH (1) PH12012501539B1 (fr)
PL (2) PL2340828T3 (fr)
PT (2) PT1948158E (fr)
RU (1) RU2503668C2 (fr)
SG (1) SG10201402055YA (fr)
SI (2) SI2340828T1 (fr)
TN (1) TNSN07264A1 (fr)
TW (2) TWI554504B (fr)
WO (1) WO2007056546A1 (fr)

Families Citing this family (191)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2007106708A2 (fr) * 2006-03-10 2007-09-20 Novartis Ag Combinaison de composes organiques
TW200838501A (en) 2007-02-02 2008-10-01 Theravance Inc Dual-acting antihypertensive agents
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
TWI406850B (zh) 2007-06-05 2013-09-01 Theravance Inc 雙效苯并咪唑抗高血壓劑
US7834041B2 (en) 2007-09-07 2010-11-16 Theravance, Inc. Dual-acting antihypertensive agents
NZ584686A (en) 2007-11-06 2013-03-28 Novartis Ag Compositions of trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl) propionate(S)-3'-methyl-2' -(pentanoyl{ 2 -(tetrazol-5-ylate)biphenyl-4'-ylmethyl} amino)butyrate]hemipentahydrate
ATE555099T1 (de) * 2007-12-11 2012-05-15 Theravance Inc Dual wirkende benzimidazol-derivate und deren verwendung als blutdrucksenkende mittel
PE20091364A1 (es) * 2008-01-17 2009-10-13 Novartis Ag Proceso para la preparacion de inhibidores de nep
JP2011518884A (ja) 2008-04-29 2011-06-30 セラヴァンス， インコーポレーテッド 二重活性抗高血圧剤
EP2334651A2 (fr) * 2008-07-24 2011-06-22 Theravance, Inc. Agents anti-hypertensifs à double action
EP2435402B1 (fr) 2009-05-28 2016-04-13 Novartis AG Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine
JP5420761B2 (ja) 2009-05-28 2014-02-19 ノバルティス アーゲー ネプリリシン阻害剤としての置換アミノプロピオン酸誘導体
JP5833000B2 (ja) 2009-07-07 2015-12-16 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー 二重に作用するピラゾール抗高血圧症薬
ES2441419T3 (es) 2009-07-22 2014-02-04 Theravance, Inc. Agentes antihipertensivos de doble acción basados en oxazol
EP2281558A1 (fr) * 2009-08-06 2011-02-09 Laboratorios Del. Dr. Esteve, S.A. Composés pharmaceutique de O-desméthyl-tramadol et inhibiteurs COX
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
JP2013517295A (ja) 2010-01-19 2013-05-16 セラヴァンス， インコーポレーテッド 二重に作用するチオフェン、ピロール、チアゾールおよびフラン抗高血圧症薬
BR112013004192A2 (pt) * 2010-08-24 2016-05-10 Novartis Ag tratamento de hipertensão e/ou prevenção ou tratamento de falha do coração em um mamífero que recebe terapia de anticoagulante
CN103189362B (zh) 2010-11-10 2015-03-11 施万生物制药研发Ip有限责任公司 烷氧基咪唑-1-基甲基联苯羧酸的结晶形式
US8877815B2 (en) * 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) * 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
CN103261168B (zh) 2010-12-15 2015-08-05 施万生物制药研发Ip有限责任公司 脑啡肽酶抑制剂
HUE028051T2 (hu) 2010-12-15 2016-11-28 Theravance Biopharma R&D Ip Llc Neprilizin inhibitorok
JP5959066B2 (ja) 2011-02-17 2016-08-02 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ネプリライシン阻害剤としての置換アミノ酪酸誘導体
ES2582640T3 (es) 2011-02-17 2016-09-14 Theravance Biopharma R&D Ip, Llc Derivados aminobutíricos sustituidos como inhibidores de neprilisina
EP2709597A2 (fr) 2011-05-13 2014-03-26 Emotional Brain B.V. Système d'administration de médicament
CN103748070B (zh) 2011-05-31 2015-06-24 施万生物制药研发Ip有限责任公司 脑啡肽酶抑制剂
CA2835216A1 (fr) 2011-05-31 2012-12-06 Theravance, Inc. Inhibiteurs de neprilysine
JP5959075B2 (ja) 2011-05-31 2016-08-02 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ネプリライシン阻害剤
TWI560172B (en) 2011-11-02 2016-12-01 Theravance Biopharma R&D Ip Llc Neprilysin inhibitors
AR089954A1 (es) 2012-02-15 2014-10-01 Theravance Inc Forma cristalina del ester 5-metil-2-oxo-[1,3]dioxol-4-ilmetilico del acido (2s,4r)-5-bifenil-4-il-2-hidroximetil-2-metil-4-[(1h-[1,2,3]triazol-4-carbonil)amino]pentanoico
US9271965B2 (en) 2012-03-28 2016-03-01 Theravance Biopharma R&D Ip, Llc Crystalline forms of (R)-3-[N-(3'-chlorobiphenyl-4-ylmethyl)-N'-(3-hydroxyisoxazole-5-carbonyl)hydrazino]-2-hydroxyproprionic acid isopropyl ester
EP2649996A1 (fr) * 2012-04-11 2013-10-16 Laboratorios Del. Dr. Esteve, S.A. Formes cristallines de sartans de type Telmisartan avec des bêta-bloquants
CN104350052B (zh) 2012-05-31 2017-05-31 施万生物制药研发Ip有限责任公司 一氧化氮供体脑啡肽酶抑制剂
CN104470521B (zh) 2012-06-08 2017-04-12 施万生物制药研发Ip有限责任公司 脑啡肽酶抑制剂
LT2864292T (lt) 2012-06-08 2017-07-10 Theravance Biopharma R&D Ip, Llc Neprilizino inhibitoriai
KR102104954B1 (ko) 2012-08-08 2020-04-27 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 네프릴리신 억제제
CA2882771C (fr) * 2012-08-24 2021-02-23 Novartis Ag Inhibiteurs de nep pour le traitement de maladies caracterisees par un agrandissement atrial ou une remodelisation atriale
EA028583B1 (ru) 2013-02-14 2017-12-29 Новартис Аг Замещенные бис-фенилбутановые производные фосфоновой кислоты в качестве ингибиторов nep (нейтральная эндопептидаза)
AU2014216417B2 (en) 2013-02-14 2016-05-12 Novartis Ag Substituted bisphenyl butanoic acid derivatives as NEP inhibitors with improved in vivo efficacy
PT2964616T (pt) 2013-03-05 2017-08-08 Theravance Biopharma R&D Ip Llc Inibidores da neprilisina
EP3038653A1 (fr) * 2013-08-26 2016-07-06 Novartis AG Nouvelle utilisation
RS59816B1 (sr) * 2013-08-26 2020-02-28 Novartis Ag Nova primena
KR20160113291A (ko) 2014-01-30 2016-09-28 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 네프리리신 저해제
SG11201606057PA (en) 2014-01-30 2016-08-30 Theravance Biopharma R&D Ip Llc 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors
WO2016037552A1 (fr) * 2014-09-09 2016-03-17 上海翰森生物医药科技有限公司 Composé cristallin bloqueur de récepteur de l'angiotensine-inhibiteur d'endopeptidase neutre (arb-nepi), son procédé de préparation et son application
CN105461647B (zh) * 2014-09-28 2018-06-29 四川海思科制药有限公司 缬沙坦沙库比曲三钠盐复合物的固态形式及其制备方法和用途
CN105503760A (zh) * 2014-10-10 2016-04-20 上海翰森生物医药科技有限公司 结晶型ARB-NEPi双阳离子复合物及其制备方法和应用
PT3218351T (pt) 2014-11-14 2019-09-26 Zentiva Ks Um método para a preparação, isolamento e purificação de formas farmaceuticamente aplicáveis de ahu-377
CN110938042B (zh) * 2014-12-08 2022-12-13 苏州晶云药物科技股份有限公司 一种包含缬沙坦和ahu377的三钠盐超分子复合物的新晶型及其制备方法
CN105693543B (zh) * 2014-12-15 2018-08-10 四川海思科制药有限公司 沙库比曲类衍生物、其药物组合物、制备方法及用途
WO2016051393A2 (fr) * 2014-12-26 2016-04-07 Crystal Pharmatech Inc. Forme cristalline iv de complexe supramoléculaire de trisodium comprenant du valsartan et ahu-377 ainsi que procédés associés
CN104473938B (zh) * 2014-12-30 2017-06-09 北京瑞都医药科技有限公司 一种治疗慢性心衰药物及其制备方法
WO2016116942A1 (fr) 2015-01-20 2016-07-28 Anlon Chemical Research Organization Nouveaux composés pharmaceutiques comprenant du ticagrélor avec des sels d'aspirine
CN105982891A (zh) * 2015-01-30 2016-10-05 王召印 阿利沙坦脂和脑啡肽酶抑制剂或其前药的药物组合物
WO2016125123A1 (fr) * 2015-02-06 2016-08-11 Mylan Laboratories Limited Sacubitril valsartan trisodique amorphe et son procédé de préparation
US9433598B2 (en) 2015-02-11 2016-09-06 Theravance Biopharma R&D Ip, Llc (2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid
CN105985225A (zh) * 2015-02-12 2016-10-05 博瑞生物医药（苏州）股份有限公司 一种lcz-696及其中间体的制备方法
CN105884644B (zh) * 2015-02-15 2020-06-09 深圳信立泰药业股份有限公司 一种中性内肽酶抑制剂盐优势形态及其制备方法
RU2715241C2 (ru) 2015-02-19 2020-02-26 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи (2r,4r)-5-(5′-хлор-2′-фторбифенил-4-ил)-2-гидрокси-4-[(5-метилоксазол-2-карбонил)амино]пентановая кислота
CN106032361A (zh) * 2015-03-11 2016-10-19 齐鲁制药有限公司 Lcz-696的新晶型及其制备方法
CN105963296B (zh) * 2015-03-12 2020-01-21 深圳信立泰药业股份有限公司 一种含有阿利沙坦酯或其盐或其水解产物或其水解产物盐的药物组合物及其用途
MX2017012110A (es) * 2015-03-20 2018-02-19 Crystal Pharmatech Co Ltd Forma cristalina de ahu377, metodo de preparacion y uso de la misma.
WO2016151525A1 (fr) * 2015-03-26 2016-09-29 Dr. Reddy’S Laboratories Limited Forme cristalline de lcz-696
SI3294283T1 (sl) * 2015-05-11 2023-07-31 Novartis Ag Režim odmerjanja sakubitril-valsartan za zdravljenje srčnega popuščanja
JP2018516267A (ja) 2015-05-29 2018-06-21 ノバルティス アーゲー 代謝性疾患を治療するためのサクビトリルおよびバルサルタン
CN104860894B (zh) * 2015-06-10 2017-05-17 北京博全健医药科技有限公司 一种抗心衰药lcz696的制备方法
US10689352B2 (en) 2015-06-12 2020-06-23 Teva Pharmaceuticals International Gmbh Solid state forms of trisodium valsartan: sacubitril
WO2016203500A2 (fr) 2015-06-19 2016-12-22 Actavis Group Ptc Ehf. Préparation de sacubitril ou de son sel et nouveaux intermédiaires dans la préparation de sacubitril
US11786498B2 (en) * 2015-07-02 2023-10-17 Novartis Ag Sacubitril calcium salts
CN106316973A (zh) * 2015-07-07 2017-01-11 江苏柯菲平医药股份有限公司 血管紧张素受体拮抗剂和nep抑制剂药物晶型及其制备
WO2017006254A1 (fr) 2015-07-08 2017-01-12 Novartis Ag Combinaison de médicaments comprenant un antagoniste du récepteur de l'angiotensine ii, un inhibiteur d'endopeptidase neutre et un antagoniste du récepteur de minéralocorticoïdes
CN106176654A (zh) * 2015-07-11 2016-12-07 凌莉 含有化合物a的固体药物组合物及其制备方法
CN106074421A (zh) * 2015-07-11 2016-11-09 凌莉 一种提高稳定性的药物组合物
CN106176725A (zh) * 2015-07-11 2016-12-07 凌莉 一种提高稳定性的药物组合物及其制备方法和用途
CN106176723A (zh) * 2015-07-11 2016-12-07 凌莉 一种固体药物组合物及其制备方法
WO2017009784A1 (fr) * 2015-07-14 2017-01-19 Cadila Healthcare Limited Formes à l'état solide de sel de trisodium du complexe valsartan/sacubitril et de sacubitril
EP3117823A1 (fr) 2015-07-17 2017-01-18 Quimica Sintetica, S.A. Dispersion solide amorphe comprenant un bloqueur du récepteur de l'angiotensine et d'un inhibiteur d'endopeptidase neutre
WO2017012600A1 (fr) 2015-07-20 2017-01-26 Zentiva, K.S. Composition pharmaceutique contenant du valsartan et du sacubitril et procédés de préparation et de stabilisation correspondants
DK3325013T4 (da) 2015-07-23 2023-10-16 Bayer Pharma AG Stimulatorer og/eller aktivatorer af den opløselige guanylatcyklase (sgc) i kombination med en inhibitor af den neutrale endopeptidase (nep inhibitor) og en angiotensin aii-antagonist og deres anvendelse
WO2017020841A1 (fr) * 2015-08-03 2017-02-09 深圳信立泰药业股份有限公司 Composition pharmaceutique contenant du lcz696 et son procédé de préparation
CN105168205A (zh) * 2015-08-18 2015-12-23 泰力特医药（湖北）有限公司 一种血管紧张素ii受体和脑啡肽酶受体双重抑制剂lcz696的制备方法
WO2017033212A1 (fr) * 2015-08-26 2017-03-02 Actavis Group Ptc Ehf. Préparation de sacubitril et de son sel et nouveau composés utilisés dans le procédé
WO2017037596A1 (fr) * 2015-08-28 2017-03-09 Dr. Reddy's Laboratories Limited Dispersion solide amorphe de lcz-696
US10596151B2 (en) 2015-08-28 2020-03-24 Novartis Ag Methods and pharmaceutical compositions for reducing arterial stiffness with a combination of a therapeutic agent blocking the angiotensin receptor and a therapeutic agent inhibiting the NEP enzyme
ES2966924T3 (es) 2015-08-28 2024-04-25 Hetero Labs Ltd Procedimiento para la preparación de un compuesto inhibidor de neprilisina-receptor de angiotensina de doble acción
WO2017042700A1 (fr) * 2015-09-07 2017-03-16 Sun Pharmaceutical Industries Limited Formes solides de valsartan et de sacubitril
WO2017051326A1 (fr) 2015-09-23 2017-03-30 Novartis Ag Nouveaux procédés et intermédiaires utiles dans la synthèse d'inhibiteurs d'endopeptidase neutre (nep)
WO2017063581A1 (fr) * 2015-10-16 2017-04-20 深圳信立泰药业股份有限公司 Préparation orale pour le traitement de maladies cardiovasculaires et son procédé de préparation
CN105669581B (zh) * 2015-11-09 2017-03-22 成都苑东生物制药股份有限公司 一种血管紧张受体拮抗剂和中性内肽酶抑制剂复合物
WO2017085573A1 (fr) 2015-11-20 2017-05-26 Lupin Limited Complexe de sacubitril-valsartan amorphe et son procédé de préparation
CN105330609B (zh) * 2015-12-07 2017-12-22 南京正大天晴制药有限公司 一种制备lcz696的方法
CN106854187B (zh) * 2015-12-08 2020-04-14 苏州晶云药物科技股份有限公司 一种ahu-377和缬沙坦三钠盐共晶水合物晶型ii的制备方法
CN105348209B (zh) 2015-12-09 2017-12-26 浙江天宇药业股份有限公司 一种抗心衰药lcz696的制备方法
EP3386945A1 (fr) 2015-12-11 2018-10-17 Zentiva, K.S. Formes solides d'ester éthylique d'acide (2r,4s)-5-(biphényl-4-yl)-4-[(3-carboxypropionyl)amino]-2-méthylpentanoïque, ses sels et son procédé de préparation
CN106905253B (zh) * 2015-12-23 2020-01-03 正大天晴药业集团股份有限公司 一种超分子复合物的结晶
CN105622535B (zh) * 2015-12-28 2018-08-03 重庆两江药物研发中心有限公司 一种lcz696的制备方法
CA3016258A1 (fr) * 2016-01-20 2017-07-27 Jie Yan Metabolite antagoniste du recepteur de l'angiotensine ii et composite inhibiteur de la nep, et procede de preparation associe
CN105646384A (zh) * 2016-01-27 2016-06-08 北京沃邦医药科技有限公司 一种脑啡肽酶抑制剂与血管紧张素ⅱ受体拮抗剂共晶化合物的精制方法
PT3411021T (pt) 2016-02-03 2025-08-06 Novartis Ag Nova utilização de uma combinação de sacubitril e valsartan
CN107033094A (zh) * 2016-02-04 2017-08-11 南京卡文迪许生物工程技术有限公司 一种药物共晶的晶型及其制备方法和组合物
WO2017141193A1 (fr) * 2016-02-16 2017-08-24 Sun Pharmaceutical Industries Limited Procédé de préparation de sacubitril ou de ses sels
WO2017154017A1 (fr) * 2016-03-07 2017-09-14 Msn Laboratories Limited Procédé de préparation du (4-{[(1s,3r)-1-([1,1'-biphényl]-4-ylméthyl)-4-éthoxy-3-méthyl-4-oxobutyl]amino}-4-oxobutanoate)-(n-pentanoyl-n-{[2'-(1h-tétrazol-1-id-5-yl)[1,1'-biphényl]-4-yl]méthyl}-l-valinate) trisodique et ses polymorphes
RS62172B1 (sr) 2016-03-08 2021-08-31 Theravance Biopharma R&D Ip Llc Kristalna (2s,4r)-5-(5’-hloro-2-fluoro-[1,1’-bifenil]-4-il)-2-(etoksimetil)-4-(3-hidroksi izoksazol-5-karboksamido)-2-metilpentanska kiselina i njene upotrebe
WO2017191620A1 (fr) * 2016-05-06 2017-11-09 Sun Pharmaceutical Industries Limited Forme cristalline d'un sel de sacubitril et procédé pour le préparer
WO2017191619A2 (fr) * 2016-05-06 2017-11-09 Sun Pharmaceutical Industries Limited Procédé de préparation d'un sel de sacubitril et de valsartan
EP3248592A1 (fr) 2016-05-25 2017-11-29 EB IP Hybritabs B.V. Procédé pour la préparation de systèmes d'administration de médicament comprenant un composé de testostérone présent dans une couche ou une partie externe, ainsi que de tels systèmes d'administration de médicaments
WO2018007919A1 (fr) 2016-07-05 2018-01-11 Novartis Ag Nouveau procédé pour des intermédiaires de sacubitril précoces
CN106177960B (zh) * 2016-08-01 2019-01-08 珠海赛隆药业股份有限公司（长沙）医药研发中心 血管紧张素受体拮抗剂和脑啡肽酶抑制剂的复合物及其用途
US10851059B2 (en) 2016-08-17 2020-12-01 Novartis Ag Processes and intermediates for NEP inhibitor synthesis
EP3508479A4 (fr) 2016-09-02 2020-02-19 Noratech Pharmaceuticals, Inc. Formes cristallines de sel disodique de valsartan
WO2018069833A1 (fr) 2016-10-10 2018-04-19 Laurus Labs Limited Forme amorphe stable d'un complexe de sacubitril-valsartan trisodique et ses procédés de préparation
WO2018069937A1 (fr) 2016-10-13 2018-04-19 Mylan Laboratories Limited Dispersions solides de sacubitril/valsartan trisodique et procédé de leur préparation
WO2018078592A1 (fr) 2016-10-28 2018-05-03 Biocon Limited Sacubitril/valsartan trisodique amorphe et son procédé de préparation
CN106518709A (zh) * 2016-11-07 2017-03-22 济南益新医药技术有限公司 一种无定形沙库比曲缬沙坦钠盐复合物的制备方法
EP3558930B1 (fr) 2016-12-23 2021-05-26 Novartis AG Nouveau procédé pour des intermédiaires de sacubitril précoces
WO2018119178A1 (fr) * 2016-12-23 2018-06-28 StemBios Technologies, Inc. Utilisation de cellules souches somatiques pour diminuer le taux de néprilysine
CN106674206B (zh) * 2016-12-30 2021-01-19 顾国明 一种治疗心衰的共晶体药物
CN107674038A (zh) * 2017-01-03 2018-02-09 上海博志研新药物技术有限公司 ARB‑NEPi复合物、晶型、制备方法及应用
CN106800537B (zh) 2017-01-18 2019-02-01 广东隆赋药业股份有限公司 丁苯酞-替米沙坦杂合物及其制备方法和用途
WO2018153895A1 (fr) 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Agonistes partiels sélectifs du récepteur a1 de l'adénosine en combinaison avec un inhibiteur de l'endopeptidase neutre et/ou un antagoniste du récepteur de l'angiotensine ii
WO2018178295A1 (fr) 2017-03-31 2018-10-04 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Extrudat thermofusible stable contenant du valsartan et du sacubitril
WO2018211479A1 (fr) * 2017-05-19 2018-11-22 Lupin Limited Compositions stabilisées d'inhibiteurs de l'angiotensine ii et d'inhibiteurs de l'endopeptidase neutre, et leur procédé de préparation
WO2019008485A1 (fr) 2017-07-06 2019-01-10 Mankind Pharma Ltd Composition pharmaceutique à dose fixe à base de valsartan et de sacubitril
ES2881317T3 (es) 2017-07-28 2021-11-29 Synthon Bv Composición farmacéutica que comprende sacubitrilo y valsartán
US10510575B2 (en) 2017-09-20 2019-12-17 Applied Materials, Inc. Substrate support with multiple embedded electrodes
WO2019073062A1 (fr) 2017-10-13 2019-04-18 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Comprimé contenant du valsartan et du sacubitril
CN107935958B (zh) * 2017-11-30 2021-02-09 中国药科大学 一种缬沙坦葛根素钠盐复合物及其制备方法
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
US10555412B2 (en) 2018-05-10 2020-02-04 Applied Materials, Inc. Method of controlling ion energy distribution using a pulse generator with a current-return output stage
WO2019239432A1 (fr) 2018-06-14 2019-12-19 Cipla Limited Complexe de valsartan et de sacubitril trisodique et composition pharmaceutique extrudée à chaud comprenant celui-ci
GB201810326D0 (en) 2018-06-22 2018-08-08 Johnson Matthey Plc Crystalline form of sacubitril, its preparation and use
KR20210032437A (ko) 2018-08-23 2021-03-24 노파르티스 아게 심부전의 치료를 위한 신규한 약제학적 용도
WO2020039394A1 (fr) 2018-08-24 2020-02-27 Novartis Ag Nouvelles combinaisons de médicaments
CN109265406B (zh) * 2018-09-03 2020-09-22 石药集团中奇制药技术（石家庄）有限公司 一种沙库巴曲缬沙坦钠新晶型及其制备方法和用途
US11476145B2 (en) 2018-11-20 2022-10-18 Applied Materials, Inc. Automatic ESC bias compensation when using pulsed DC bias
KR20200073676A (ko) 2018-12-14 2020-06-24 엠에프씨 주식회사 발사탄 및 사쿠비트릴을 포함하는 고체 분산체 및 이를 포함하는 약학 조성물 및 이의 제조 방법
JP7451540B2 (ja) 2019-01-22 2024-03-18 アプライド マテリアルズ インコーポレイテッド パルス状電圧波形を制御するためのフィードバックループ
US11508554B2 (en) 2019-01-24 2022-11-22 Applied Materials, Inc. High voltage filter assembly
CN109912525A (zh) * 2019-03-13 2019-06-21 陈文辉 一种lcz696新晶型及其制备方法
KR102543230B1 (ko) 2019-05-24 2023-06-14 주식회사 파마코스텍 발사르탄/사쿠비트릴 3소듐염 수화물의 결정형 및 그 제조방법
CN114452287B (zh) * 2019-05-30 2023-05-12 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物的新用途
US12453719B2 (en) 2019-05-30 2025-10-28 Shenzhen Salubris Pharmaceuticals Co., Ltd. Treatment method using a complex of angiotensin II receptor antagonist metabolite and NEP inhibitor
EP3766484B1 (fr) 2019-07-19 2021-08-25 Zentiva, K.S. Forme posologique pharmaceutique solide comprenant du valsartan et du sacubitril
CA3151788A1 (fr) 2019-09-20 2021-03-25 Jingchao Sun Utilisations d'un complexe constitue d'un metabolite antagoniste du recepteur de l'angiotensine ii et d'un inhibiteur de la nep dans le traitement de l'insuffisance cardiaque
US11969424B2 (en) 2019-12-16 2024-04-30 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
CN114945564B (zh) * 2020-01-19 2023-06-30 深圳信立泰药业股份有限公司 Arb代谢产物与nep抑制剂的复合物新晶型及其制备方法
KR102149125B1 (ko) 2020-02-05 2020-08-28 유니셀랩 주식회사 새로운 사쿠비트릴 칼슘/발사르탄 공동무정형
KR20210101164A (ko) 2020-02-07 2021-08-18 보령제약 주식회사 하이브리드 화합물 및 그 제조방법
KR20200020746A (ko) 2020-02-07 2020-02-26 보령제약 주식회사 하이브리드 화합물 및 그 제조방법
CN111253330B (zh) * 2020-02-29 2023-01-24 广州白云山天心制药股份有限公司 沙坦类药物的新晶型及其制备方法和用途
KR20210120560A (ko) 2020-03-27 2021-10-07 주식회사 유영제약 고함량의 주성분을 포함하는 정제 및 그 제조방법
KR102155474B1 (ko) 2020-04-28 2020-09-11 유니셀랩 주식회사 사쿠비트릴/발사르탄 공동무정형
JP7064527B2 (ja) * 2020-05-01 2022-05-10 ノバルティス アーゲー サクビトリルカルシウム塩
CN116036079A (zh) * 2020-06-18 2023-05-02 深圳信立泰药业股份有限公司 一种复合物的药物组合物及其制备方法
KR20220012821A (ko) 2020-07-23 2022-02-04 주식회사 종근당 이중 작용 복합 화합물의 결정형 및 이의 제조방법
KR102215623B1 (ko) * 2020-07-24 2021-02-15 유니셀랩 주식회사 사쿠비트릴 칼슘염 및 사쿠비트릴 유리염기와 발사르탄을 공동분자로 사용한 새로운 신규 공결정 형태
US11462388B2 (en) 2020-07-31 2022-10-04 Applied Materials, Inc. Plasma processing assembly using pulsed-voltage and radio-frequency power
CN115443272B (zh) * 2020-08-17 2023-11-17 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物的心衰应用
KR102858594B1 (ko) 2020-10-08 2025-09-11 한미약품 주식회사 사쿠비트릴 및 발사르탄 나트륨염을 포함하는 경구용 고형제제
US11901157B2 (en) 2020-11-16 2024-02-13 Applied Materials, Inc. Apparatus and methods for controlling ion energy distribution
US11798790B2 (en) 2020-11-16 2023-10-24 Applied Materials, Inc. Apparatus and methods for controlling ion energy distribution
CN115461052B (zh) * 2020-11-25 2023-12-22 深圳信立泰药业股份有限公司 Arb代谢产物与nep抑制剂的复合物预防和/或治疗肾病的药物用途
KR20220091767A (ko) 2020-12-24 2022-07-01 주식회사 보령 사쿠비트릴 발사르탄 하이브리드 화합물 또는 그 약제학적으로 허용되는 염을 유효성분으로 포함하는 약제학적 조성물
KR102486815B1 (ko) 2021-01-20 2023-01-10 주식회사 대웅제약 Nep 저해제 및 arb를 포함하는 약학 조성물 및 이의 제조 방법
US11495470B1 (en) 2021-04-16 2022-11-08 Applied Materials, Inc. Method of enhancing etching selectivity using a pulsed plasma
WO2022224274A1 (fr) 2021-04-20 2022-10-27 Mylan Laboratories Limited Formes polymorphes de sacubitril-telmisartan (1 : 1)
US11948780B2 (en) 2021-05-12 2024-04-02 Applied Materials, Inc. Automatic electrostatic chuck bias compensation during plasma processing
US11791138B2 (en) 2021-05-12 2023-10-17 Applied Materials, Inc. Automatic electrostatic chuck bias compensation during plasma processing
US11967483B2 (en) 2021-06-02 2024-04-23 Applied Materials, Inc. Plasma excitation with ion energy control
US11984306B2 (en) 2021-06-09 2024-05-14 Applied Materials, Inc. Plasma chamber and chamber component cleaning methods
US20220399186A1 (en) 2021-06-09 2022-12-15 Applied Materials, Inc. Method and apparatus to reduce feature charging in plasma processing chamber
US12148595B2 (en) 2021-06-09 2024-11-19 Applied Materials, Inc. Plasma uniformity control in pulsed DC plasma chamber
US11810760B2 (en) 2021-06-16 2023-11-07 Applied Materials, Inc. Apparatus and method of ion current compensation
US11569066B2 (en) 2021-06-23 2023-01-31 Applied Materials, Inc. Pulsed voltage source for plasma processing applications
US11776788B2 (en) 2021-06-28 2023-10-03 Applied Materials, Inc. Pulsed voltage boost for substrate processing
KR102756994B1 (ko) 2021-07-22 2025-01-22 대봉엘에스 주식회사 사쿠비트릴, 발사르탄, 및 니코틴아미드의 공동무정형
KR102399717B1 (ko) 2021-08-10 2022-05-19 대봉엘에스 주식회사 사쿠비트릴 및 아질사르탄 복합 약제학적 조성물, 및 이의 제조방법
US11476090B1 (en) 2021-08-24 2022-10-18 Applied Materials, Inc. Voltage pulse time-domain multiplexing
TW202327582A (zh) * 2021-08-26 2023-07-16 大陸商深圳信立泰藥業股份有限公司 ＡＲＮｉ與鈣離子拮抗劑的藥物組合物及其用途
US12106938B2 (en) 2021-09-14 2024-10-01 Applied Materials, Inc. Distortion current mitigation in a radio frequency plasma processing chamber
US11694876B2 (en) 2021-12-08 2023-07-04 Applied Materials, Inc. Apparatus and method for delivering a plurality of waveform signals during plasma processing
US20250064799A1 (en) 2021-12-31 2025-02-27 Tenax Therapeutics, Inc. Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction
US11972924B2 (en) 2022-06-08 2024-04-30 Applied Materials, Inc. Pulsed voltage source for plasma processing applications
US12315732B2 (en) 2022-06-10 2025-05-27 Applied Materials, Inc. Method and apparatus for etching a semiconductor substrate in a plasma etch chamber
US12272524B2 (en) 2022-09-19 2025-04-08 Applied Materials, Inc. Wideband variable impedance load for high volume manufacturing qualification and on-site diagnostics
US12111341B2 (en) 2022-10-05 2024-10-08 Applied Materials, Inc. In-situ electric field detection method and apparatus
EP4691459A1 (fr) 2023-04-05 2026-02-11 Hanmi Pharm. Co., Ltd. Formulation combinée comprenant du sacubitril-valsartan et un inhibiteur de sglt-2 ayant une stabilité et un taux de dissolution améliorés
KR20250066976A (ko) * 2023-11-07 2025-05-14 주식회사 노브메타파마 아연염 및 사이클로-히스프로를 유효성분으로 포함하는 당뇨병성 신증의 예방, 개선 또는 치료용 조성물
EP4652990A1 (fr) 2024-05-24 2025-11-26 Genepharm S.A. Emballage de composition solide de valsartan et de sacubitril

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2499058A (en) 1950-02-28 B-haloxantfflne salts of diarylalkyl
US1954909A (en) 1929-11-14 1934-04-17 Adler Oscar Processes for the producing of molecular compounds of the salts of phenyl-quinolinecarboxylic acids with alkylated pyrazolones and alkylated amino-pyrazolones
NL76613C (fr) 1948-07-01
US2534813A (en) 1950-01-21 1950-12-19 Searle & Co 8-haloxanthine salts of cyclic-aminoalkyl benzohydryl ethers and the production thereof
US3057731A (en) 1958-03-27 1962-10-09 Skanska Attikfabriken Ab Preparation of bakery products
DE3063328D1 (en) 1979-08-20 1983-07-07 Abbott Lab Mixed salt of valproic acid
US4610816A (en) 1980-12-18 1986-09-09 Schering Corporation Substituted dipeptides as inhibitors of enkephalinases
DE3116334A1 (de) * 1981-04-24 1982-11-18 Gefra B.V.,, s'Gravenzande "vorrichtung zum befestigen einer seitenfuehrung, einer foerdereinrichtung an einer stuetze"
ZA84670B (en) 1983-01-31 1985-09-25 Merck & Co Inc Thiorphan analogs as enkephalinase and angiotensin converting enzyme inhibitors
US4722810A (en) 1984-08-16 1988-02-02 E. R. Squibb & Sons, Inc. Enkephalinase inhibitors
US4929641B1 (en) 1988-05-11 1994-08-30 Schering Corp Mercapto-acylamino acid antihypertensives
US4749688A (en) 1986-06-20 1988-06-07 Schering Corporation Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension
US4740499A (en) 1986-07-28 1988-04-26 Monsanto Company Method of enhancing the bioactivity of atrial peptides
GB8811873D0 (en) 1988-05-19 1988-06-22 Pfizer Ltd Therapeutic agents
GB2218983A (en) 1988-05-27 1989-11-29 Pfizer Ltd Spiro-substituted glutaramides as diuretics
GB8812597D0 (en) 1988-05-27 1988-06-29 Pfizer Ltd Therapeutic agents
EP0361365A1 (fr) 1988-09-30 1990-04-04 E.R. SQUIBB & SONS, INC. Composés d'acides aminobenzoiques et aminocyclohexane carboxyliques, compositions, et méthode d'application
GB8903740D0 (en) 1989-02-18 1989-04-05 Pfizer Ltd Therapeutic agents
PH30484A (en) 1990-02-19 1997-05-28 Ciba Geigy Acy compounds pharmaceutical composition containing said compound and method of use thereof
FR2658571B1 (fr) 1990-02-21 1992-04-24 Bendix Europ Services Tech
US5223516A (en) 1990-03-22 1993-06-29 E. R. Squibb & Sons, Inc. 3,3,3-trifluoro-2-mercaptomethyl-N-tetrazolyl substituted propanamides and method of using same
HUT59656A (en) 1990-11-15 1992-06-29 Puetter Medice Chem Pharm Process for producing s/+/-phenyl-alkanoic acids and alpha-amino-acids containing complexes and pharmaceutical compositions containing them as active components
EP0498361A3 (en) * 1991-02-06 1992-09-02 Schering Corporation Combination of an angiotensin ii antagonist or renin inhibitor with a neutral endopeptidase inhibitor
GB9103454D0 (en) 1991-02-19 1991-04-03 Pfizer Ltd Therapeutic agents
AU1870292A (en) 1991-04-16 1992-11-17 Schering Corporation Use of neutral endopeptidase inhibitors in the treatment of nephrotoxicity
US5294632A (en) 1991-05-01 1994-03-15 Ciba-Geigy Corporation Phosphono/biaryl substituted dipetide derivatives
US5225401A (en) 1991-08-12 1993-07-06 E. R. Squibb & Sons, Inc. Treatment of congestive heart failure
US5250522A (en) 1992-10-09 1993-10-05 Ciba-Geigy Corporation Phosphono/biaryl substituted amino acid derivatives
US5273990A (en) 1992-09-03 1993-12-28 Ciba-Geigy Corporation Phosphono substituted tetrazole derivatives
GB9123353D0 (en) 1991-11-04 1991-12-18 Fujisawa Pharmaceutical Co New mercapto-amide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
WO1993010773A1 (fr) 1991-12-06 1993-06-10 Schering-Plough S.P.A. Utilisation d'inhibiteurs d'endopeptidases neutres dans le traitement de l'hipertrophie ventriculaire gauche
US5217996A (en) * 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
US5376293A (en) 1992-09-14 1994-12-27 State Of South Dakota As Represented By The Department Of Transportation Deicer
DE4233296C1 (de) 1992-10-02 1994-03-31 Heitland Und Petre Int Gmbh Behälter für Kosmetikprodukte
WO1994015908A1 (fr) 1993-01-14 1994-07-21 Yoshitomi Pharmaceutical Industries, Ltd. Derive de propionamide et son utilisation medicinale
JPH06234754A (ja) 1993-02-10 1994-08-23 Dai Ichi Seiyaku Co Ltd 複素環式カルボン酸誘導体
CN1046119C (zh) 1993-07-22 1999-11-03 中国科学院广州电子技术研究所 聚磷酸盐复盐及其制造方法
IT1266571B1 (it) 1993-07-30 1997-01-09 Zambon Spa Derivati della beta-mercapto-propanammide utili nel trattamento delle malattie cardiovascolari
JP2810302B2 (ja) 1993-10-01 1998-10-15 ティーディーケイ株式会社 小型ポンプ
JP3576193B2 (ja) 1993-12-03 2004-10-13 第一製薬株式会社 ビフェニルメチル置換バレリルアミド誘導体
CA2168066A1 (fr) 1995-02-08 1996-08-09 James R. Powell Traitement de l'hypertension et de l'insuffisance cardiaque globale
US6558699B2 (en) 1997-11-17 2003-05-06 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
DE69926750T2 (de) 1998-06-17 2006-06-29 Bristol-Myers Squibb Co. Vorbeugung des hirninfarkts durch kombinierte verabreichung von adp-rezeptor antiblutplättchen und antihypertensiven medikamenten
SK285863B6 (sk) 1998-07-10 2007-10-04 Novartis Ag Kombinovaná farmaceutická kompozícia obsahujúca AT1-antagonistu valsartan a amlodipín
CN1069647C (zh) 1998-08-31 2001-08-15 靳广毅 一种具有广谱抗菌作用的化合物及其用途
CZ20014229A3 (cs) 1999-05-27 2003-01-15 Pfizer Products Inc. Společná proléčiva amlodipinu a atorvastatinu
HN2000000050A (es) 1999-05-27 2001-02-02 Pfizer Prod Inc Sal mutua de amlodipino y atorvastatina
JP2003533440A (ja) * 2000-04-03 2003-11-11 ブリストル−マイヤーズ スクイブ カンパニー 隔離心収縮期高血圧症を処置するバソペプチダーゼ抑制剤
MXPA03000525A (es) * 2000-07-19 2003-05-14 Novartis Ag Sales de valsartan.
DE10050246C1 (de) 2000-10-11 2002-06-20 Nutrinova Gmbh Calciumdoppelsalze, Verfahren zu ihrer Herstellung und ihre Verwendung zur Konservierung
US6737430B2 (en) 2000-11-09 2004-05-18 Pfizer, Inc. Mutual prodrug of amlodipine and atorvastatin
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
DE60209343T2 (de) 2001-04-11 2006-10-26 Bristol-Myers Squibb Co. Aminosäurekomplexe von c-arylglycosiden zur behandlung von diabetes und verfahren
US6777443B2 (en) 2001-05-15 2004-08-17 Novartis Ag Dipeptide derivatives
WO2003035046A2 (fr) 2001-10-18 2003-05-01 Novartis Ag Composes organiques
IL162661A0 (en) 2002-01-17 2005-11-20 Novartis Ag Pharmaceutical compositions comprising valsartan and nep inhibitors
US6869970B2 (en) 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
US7446107B2 (en) 2002-02-15 2008-11-04 Transform Pharmaceuticals, Inc. Crystalline forms of conazoles and methods of making and using the same
AU2003213719A1 (en) 2002-03-01 2003-09-16 Regents Of The University Of Michigan Multiple-component solid phases containing at least one active pharmaceutical ingredient
WO2003089417A1 (fr) 2002-04-15 2003-10-30 Dr. Reddy's Laboratories Limited Nouvelles formes cristallines de (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- [2'-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl] amine (valsartan)
TWI299663B (en) 2002-05-14 2008-08-11 Novartis Ag Methods of treatment
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
WO2003097098A1 (fr) 2002-05-17 2003-11-27 Novartis Ag Composition pharmaceutique comprenant un inhibiteur de renine, un agent de blocage du canal du calcium et un diuretique
CN1159313C (zh) 2002-08-27 2004-07-28 何广卫 地洛他定多元酸碱金属或碱土金属盐复合盐及其药用组合物
GB0230025D0 (en) 2002-12-23 2003-01-29 Pfizer Ltd Novel pharmaceuticals
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
JP4923182B2 (ja) 2003-02-28 2012-04-25 マクニール−ピーピーシー・インコーポレーテツド セレコキシブ及びニコチンアミド共結晶並びにこの共結晶を含む医薬組成物
DE602004013405T2 (de) 2003-03-17 2009-05-07 Teva Pharmaceutical Industries Ltd. Polymorphe formen von valsartan
AU2003223106A1 (en) 2003-03-31 2004-10-25 Hetero Drugs Limited A novel amorphous form of valsartan
CN1247596C (zh) 2003-05-15 2006-03-29 中国药品生物制品检定所 一种具有螯合结晶水合物的头孢菌素及其制备方法
TW200509909A (en) * 2003-05-16 2005-03-16 Novartis Ag Use of organic compounds
WO2005049587A1 (fr) 2003-11-21 2005-06-02 Ranbaxy Laboratories Limited Procede de preparation de tetrazole de biphenyle
CN1246482C (zh) 2004-05-08 2006-03-22 山东大学齐鲁医院 单个核细胞白细胞相容性抗原a和b特异核糖核酸检测方法
CN1279045C (zh) 2004-07-30 2006-10-11 广州白云山制药股份有限公司 头孢硫脒复盐及其制造方法
CN100500669C (zh) 2004-12-10 2009-06-17 山东大学 一种丹酚酸黄连素复盐及其制备方法与应用
MY146830A (en) 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
JP2006234754A (ja) 2005-02-28 2006-09-07 Tokyo Keiso Co Ltd 超音波流量計
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
CN100391961C (zh) 2005-11-16 2008-06-04 天津大学 五水头孢唑林钠晶体结构及晶体分子组装制备方法
JP2007157459A (ja) 2005-12-02 2007-06-21 Sony Corp 非水電解質電池
WO2016037552A1 (fr) 2014-09-09 2016-03-17 上海翰森生物医药科技有限公司 Composé cristallin bloqueur de récepteur de l'angiotensine-inhibiteur d'endopeptidase neutre (arb-nepi), son procédé de préparation et son application
CN105503760A (zh) * 2014-10-10 2016-04-20 上海翰森生物医药科技有限公司 结晶型ARB-NEPi双阳离子复合物及其制备方法和应用
CN110938042B (zh) 2014-12-08 2022-12-13 苏州晶云药物科技股份有限公司 一种包含缬沙坦和ahu377的三钠盐超分子复合物的新晶型及其制备方法
WO2016125123A1 (fr) 2015-02-06 2016-08-11 Mylan Laboratories Limited Sacubitril valsartan trisodique amorphe et son procédé de préparation
MX2017012110A (es) 2015-03-20 2018-02-19 Crystal Pharmatech Co Ltd Forma cristalina de ahu377, metodo de preparacion y uso de la misma.
US10689352B2 (en) 2015-06-12 2020-06-23 Teva Pharmaceuticals International Gmbh Solid state forms of trisodium valsartan: sacubitril
WO2017009784A1 (fr) 2015-07-14 2017-01-19 Cadila Healthcare Limited Formes à l'état solide de sel de trisodium du complexe valsartan/sacubitril et de sacubitril
CN105037289B (zh) 2015-07-17 2017-08-22 华东理工大学 血管紧张素受体拮抗剂和中性内肽酶抑制剂超分子复合体的新晶型
WO2017042700A1 (fr) 2015-09-07 2017-03-16 Sun Pharmaceutical Industries Limited Formes solides de valsartan et de sacubitril
CN106905253B (zh) * 2015-12-23 2020-01-03 正大天晴药业集团股份有限公司 一种超分子复合物的结晶
WO2017154017A1 (fr) 2016-03-07 2017-09-14 Msn Laboratories Limited Procédé de préparation du (4-{[(1s,3r)-1-([1,1'-biphényl]-4-ylméthyl)-4-éthoxy-3-méthyl-4-oxobutyl]amino}-4-oxobutanoate)-(n-pentanoyl-n-{[2'-(1h-tétrazol-1-id-5-yl)[1,1'-biphényl]-4-yl]méthyl}-l-valinate) trisodique et ses polymorphes
WO2018069833A1 (fr) 2016-10-10 2018-04-19 Laurus Labs Limited Forme amorphe stable d'un complexe de sacubitril-valsartan trisodique et ses procédés de préparation
CN107674038A (zh) 2017-01-03 2018-02-09 上海博志研新药物技术有限公司 ARB‑NEPi复合物、晶型、制备方法及应用
CN109912525A (zh) 2019-03-13 2019-06-21 陈文辉 一种lcz696新晶型及其制备方法

Also Published As

Publication number Publication date
HRP20140274T1 (hr) 2014-04-25
SG10201402055YA (en) 2014-09-26
PL1948158T3 (pl) 2014-06-30
MY145462A (en) 2012-02-15
CN101098689B (zh) 2013-02-13
GT200700055A (es) 2008-09-24
ES2449765T3 (es) 2014-03-21
US20160324821A1 (en) 2016-11-10
TW200803834A (en) 2008-01-16
US20190374497A1 (en) 2019-12-12
EP1948158B1 (fr) 2014-01-29
US20200016109A1 (en) 2020-01-16
LTC1948158I2 (lt) 2022-09-12
BRPI0605921B1 (pt) 2020-08-18
EP1948158A1 (fr) 2008-07-30
AU2006311481A1 (en) 2007-05-18
IL184027A0 (en) 2007-10-31
IL184027A (en) 2014-11-30
JP2008542447A (ja) 2008-11-27
US20250339395A1 (en) 2025-11-06
KR101549318B1 (ko) 2015-09-01
CY2016014I1 (el) 2016-08-31
LTPA2021502I1 (lt) 2021-02-10
US20150057322A1 (en) 2015-02-26
PE20190374A1 (es) 2019-03-08
PH12012501539A1 (en) 2013-06-17
KR20130116381A (ko) 2013-10-23
CA2590511A1 (fr) 2007-05-18
US20210361610A1 (en) 2021-11-25
CN102702119B (zh) 2016-01-20
HUE050870T2 (hu) 2021-01-28
JO3492B1 (ar) 2020-07-05
KR20080075055A (ko) 2008-08-14
US20180344679A1 (en) 2018-12-06
US11096918B2 (en) 2021-08-24
BRPI0605921B8 (pt) 2021-05-25
NO340315B1 (no) 2017-03-27
PL2340828T3 (pl) 2021-02-22
NZ600626A (en) 2013-11-29
AR057882A1 (es) 2007-12-26
KR101432821B1 (ko) 2014-08-26
NO20151656A1 (no) 2007-09-10
SI2340828T1 (sl) 2020-11-30
PH12012501539B1 (en) 2019-07-17
MA30128B1 (fr) 2009-01-02
BRPI0605921A2 (pt) 2009-05-26
NZ594006A (en) 2012-07-27
US20200016110A1 (en) 2020-01-16
FR21C1000I1 (fr) 2021-03-05
HK1175465A1 (zh) 2013-07-05
RU2503668C2 (ru) 2014-01-10
US11642329B2 (en) 2023-05-09
TWI554504B (zh) 2016-10-21
TW201402111A (zh) 2014-01-16
SI1948158T1 (sl) 2014-04-30
BR122013025375B1 (pt) 2020-12-01
CN102702119A (zh) 2012-10-03
LTC2340828I2 (lt) 2024-05-10
FR16C0018I2 (fr) 2017-12-08
PT2340828T (pt) 2020-10-19
NO20073396L (no) 2007-09-10
WO2007056546A1 (fr) 2007-05-18
HRP20201605T1 (hr) 2020-12-25
NO2016008I2 (no) 2016-05-18
CY2021003I2 (el) 2023-11-15
FR16C0018I1 (fr) 2016-06-24
IL219782A0 (en) 2012-06-28
JP4824754B2 (ja) 2011-11-30
NO2016008I1 (no) 2016-05-18
US9388134B2 (en) 2016-07-12
NO337288B1 (no) 2016-02-29
US8877938B2 (en) 2014-11-04
HK1121371A1 (en) 2009-04-24
CN101098689A (zh) 2008-01-02
DK1948158T3 (en) 2014-03-10
EP2340828A1 (fr) 2011-07-06
CY2021003I1 (el) 2021-05-05
RU2012107219A (ru) 2013-09-10
US20190374498A1 (en) 2019-12-12
DK2340828T3 (da) 2020-10-12
BR122013025375B8 (pt) 2021-05-25
PE20070803A1 (es) 2007-09-10
EP3685833A1 (fr) 2020-07-29
HUS2100003I1 (hu) 2021-03-01
HUS1600025I1 (hu) 2016-06-28
TNSN07264A1 (en) 2008-12-31
CY1115004T1 (el) 2016-08-31
FR21C1000I2 (fr) 2024-05-24
US20220257551A1 (en) 2022-08-18
TWI418348B (zh) 2013-12-11
EP2340828B1 (fr) 2020-07-15
PT1948158E (pt) 2014-04-04
US20090156585A1 (en) 2009-06-18
AU2006311481B2 (en) 2010-02-25
JP2011252013A (ja) 2011-12-15
LT2340828T (lt) 2020-11-10
JP2015098485A (ja) 2015-05-28
US20220331282A1 (en) 2022-10-20
MX2007008075A (es) 2007-07-13
ECSP14019136A (es) 2015-12-31
ES2823749T3 (es) 2021-05-10
CY1123531T1 (el) 2021-05-05
CA2590511C (fr) 2013-01-08

Similar Documents

Publication Publication Date Title
BE2023C529I2 (fr)
BE2021C557I2 (fr)
BE2021C524I2 (fr)
BE2021C519I2 (fr)
LUC00195I2 (fr)
BE2020C531I2 (fr)
BE2020C511I2 (fr)
BE2020C508I2 (fr)
BE2020C004I2 (fr)
BE2019C521I2 (fr)
BE2019C503I2 (fr)
BE2019C533I2 (fr)
BE2014C012I2 (fr)
BE2014C057I2 (fr)
BE2013C074I2 (fr)
BRPI0601358B8 (pt) Aplicador de clipe cirúrgico
BRPI0601402B8 (pt) Aplicador de grampos cirúrgicos
BR122017004707A2 (fr)
BRPI0609157A8 (fr)
BE2019C013I2 (fr)
BRPI0608519A2 (fr)
BR122016029989A2 (fr)
BRPI0604219A (fr)
JP2005235773A5 (fr)
BRPI0618215B8 (fr)